Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan;72(1):48-56.
doi: 10.1136/thoraxjnl-2016-208655. Epub 2016 Jun 30.

Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval

Uraujh Yousaf-Khan  1 , Carlijn van der Aalst  1 , Pim A de Jong  2 , Marjolein Heuvelmans  3   4 , Ernst Scholten  2   5 , Jan-Willem Lammers  6 , Peter van Ooijen  3   4 , Kristiaan Nackaerts  7 , Carla Weenink  8 , Harry Groen  9 , Rozemarijn Vliegenthart  3   4 , Kevin Ten Haaf  1 , Matthijs Oudkerk  3   4 , Harry de Koning  1
Affiliations
Randomized Controlled Trial

Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval

Uraujh Yousaf-Khan et al. Thorax. 2017 Jan.

Abstract

Background: In the USA annual lung cancer screening is recommended. However, the optimal screening strategy (eg, screening interval, screening rounds) is unknown. This study provides results of the fourth screening round after a 2.5-year interval in the Dutch-Belgian Lung Cancer Screening trial (NELSON).

Methods: Europe's largest, sufficiently powered randomised lung cancer screening trial was designed to determine whether low-dose CT screening reduces lung cancer mortality by ≥25% compared with no screening after 10 years of follow-up. The screening arm (n=7915) received screening at baseline, after 1 year, 2 years and 2.5 years. Performance of the NELSON screening strategy in the final fourth round was evaluated. Comparisons were made between lung cancers detected in the first three rounds, in the final round and during the 2.5-year interval.

Results: In round 4, 46 cancers were screen-detected and there were 28 interval cancers between the third and fourth screenings. Compared with the second round screening (1-year interval), in round 4 a higher proportion of stage IIIb/IV cancers (17.3% vs 6.8%, p=0.02) and higher proportions of squamous-cell, bronchoalveolar and small-cell carcinomas (p=0.001) were detected. Compared with a 2-year interval, the 2.5-year interval showed a higher non-significant stage distribution (stage IIIb/IV 17.3% vs 5.2%, p=0.10). Additionally, more interval cancers manifested in the 2.5-year interval than in the intervals of previous rounds (28 vs 5 and 28 vs 19).

Conclusions: A 2.5-year interval reduced the effect of screening: the interval cancer rate was higher compared with the 1-year and 2-year intervals, and proportion of advanced disease stage in the final round was higher compared with the previous rounds.

Trial registration number: ISRCTN63545820.

Keywords: Clinical Epidemiology; Lung Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Tobacco and the lung.

PubMed Disclaimer

Comment in

Publication types

Associated data